Revance to Participate in the 39th Annual J.P. Morgan Healthcare Conference
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company specializing in aesthetic and therapeutic innovations, will join the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021. CEO Mark Foley is set to present at 12:40 p.m. PT / 3:40 p.m. ET. The live audio webcast can be accessed on their Investor Relations page, with a replay available for 30 days post-presentation. Revance is advancing its DaxibotulinumtoxinA for Injection, currently seeking U.S. regulatory approval after completing a Phase 3 trial for glabellar lines.
- None.
- None.
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the 39th Annual J.P. Morgan Healthcare Conference, a fully virtual management access conference.
President and Chief Executive Officer, Mark Foley, is scheduled to present on Thursday, January 14, at 12:40 p.m. PT / 3:40 p.m. ET.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.
About Revance Therapeutics, Inc.
Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow's feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which includes integrated smart payment, subscription and loyalty digital services. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.
"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.
BOTOX® is a registered trademark of Allergan, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005027/en/
FAQ
When will Revance Therapeutics present at the J.P. Morgan Healthcare Conference?
How can I access the Revance Therapeutics conference presentation?
What product is Revance Therapeutics seeking U.S. regulatory approval for?
What indications is DaxibotulinumtoxinA being evaluated for?
What unique offerings does Revance Therapeutics provide?
